Medpace Holdings, Inc. (MEDP) on Focus After Trading At 52-Week Highs

June 17, 2018 - By Kurt Siggers

The stock of Medpace Holdings, Inc. (NASDAQ:MEDP) hit a new 52-week high and has $49.31 target or 9.00 % above today’s $45.24 share price. The 8 months bullish chart indicates low risk for the $1.69 billion company. The 1-year high was reported on Jun, 17 by Barchart.com. If the $49.31 price target is reached, the company will be worth $152.19 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.58% or $0.26 during the last trading session, reaching $45.24. About 481,230 shares traded or 58.40% up from the average. Medpace Holdings, Inc. (NASDAQ:MEDP) has risen 55.61% since June 17, 2017 and is uptrending. It has outperformed by 43.04% the S&P500.

Analysts await Medpace Holdings, Inc. (NASDAQ:MEDP) to report earnings on July, 30. They expect $0.41 EPS, up 7.89 % or $0.03 from last year’s $0.38 per share. MEDP’s profit will be $15.33M for 27.59 P/E if the $0.41 EPS becomes a reality. After $0.60 actual EPS reported by Medpace Holdings, Inc. for the previous quarter, Wall Street now forecasts -31.67 % negative EPS growth.

More important recent Medpace Holdings, Inc. (NASDAQ:MEDP) news were published by: Benzinga.com which released: “26 Stocks Moving In Tuesday’s Pre-Market Session” on June 12, 2018, also Bizjournals.com published article titled: “Medpace reveals price of secondary offering of stock”, Globenewswire.com published: “Factors of Influence in 2018, Key Indicators and Opportunity within South Jersey Industries, SITO Mobile, Ormat …” on May 21, 2018. More interesting news about Medpace Holdings, Inc. (NASDAQ:MEDP) was released by: Benzinga.com and their article: “41 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: June 12, 2018.

Medpace Holdings, Inc. provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company has market cap of $1.69 billion. The firm offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. It has a 38.5 P/E ratio. The Company’s services include medical affairs, clinical trial management, study feasibility, study start-up, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance.

Medpace Holdings, Inc. (NASDAQ:MEDP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: